249 related articles for article (PubMed ID: 27812688)
21. Emesis induced by low or minimal emetic risk chemotherapy.
Tonato M; Clark-Snow RA; Osoba D; Del Favero A; Ballatori E; Borjeson S
Support Care Cancer; 2005 Feb; 13(2):109-11. PubMed ID: 15714358
[TBL] [Abstract][Full Text] [Related]
22. Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Italian Group for Antiemetic Research.
Ann Oncol; 1998 Jul; 9(7):759-65. PubMed ID: 9739443
[TBL] [Abstract][Full Text] [Related]
23. Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis.
Wu CE; Liaw CC
Support Care Cancer; 2012 Oct; 20(10):2357-61. PubMed ID: 22187110
[TBL] [Abstract][Full Text] [Related]
24. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.
Kris MG; Hesketh PJ; Herrstedt J; Rittenberg C; Einhorn LH; Grunberg S; Koeller J; Olver I; Borjeson S; Ballatori E
Support Care Cancer; 2005 Feb; 13(2):85-96. PubMed ID: 15565277
[TBL] [Abstract][Full Text] [Related]
25. Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with colorectal cancer receiving chemotherapy of moderate emetic risk.
Fujii H; Iihara H; Ishihara M; Takahashi T; Yoshida K; Itoh Y
Anticancer Res; 2013 Dec; 33(12):5549-56. PubMed ID: 24324096
[TBL] [Abstract][Full Text] [Related]
26. Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy.
Kris MG; Tonato M; Bria E; Ballatori E; Espersen B; Herrstedt J; Rittenberg C; Einhorn LH; Grunberg S; Saito M; Morrow G; Hesketh P
Support Care Cancer; 2011 Mar; 19 Suppl 1():S25-32. PubMed ID: 20803039
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group.
Lebeau B; Depierre A; Giovannini M; Rivière A; Kaluzinski L; Votan B; Hédouin M; d'Allens H
Ann Oncol; 1997 Sep; 8(9):887-92. PubMed ID: 9358940
[TBL] [Abstract][Full Text] [Related]
28. 2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Clark-Snow R; Ruhlmann CH; Garcia-Del-Barrio MA; Schwartzberg L; Rapoport BL; Jahn F
Support Care Cancer; 2023 Dec; 32(1):37. PubMed ID: 38110581
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of anti-emetic use in chemotherapy-induced nausea and vomiting in a third-world country (Lebanon).
Zeitoun AA; Nassif JG
J Eval Clin Pract; 2013 Feb; 19(1):68-75. PubMed ID: 21999252
[TBL] [Abstract][Full Text] [Related]
31. Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis.
Yarboro CH; Wesley R; Amantea MA; Klippel JH; Pucino F
Ann Pharmacother; 1996; 30(7-8):752-5. PubMed ID: 8826554
[TBL] [Abstract][Full Text] [Related]
32. Pattern of prophylaxis administration for chemotherapy-induced nausea and vomiting: an analysis of city-based health insurance data.
Nakamura F; Higashi T
Int J Clin Oncol; 2013 Dec; 18(6):971-6. PubMed ID: 23011102
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.
Warr DG; Street JC; Carides AD
Support Care Cancer; 2011 Jun; 19(6):807-13. PubMed ID: 20461438
[TBL] [Abstract][Full Text] [Related]
34. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
Plosker GL; Benfield P
Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
[TBL] [Abstract][Full Text] [Related]
35. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood.
Phillips RS; Gopaul S; Gibson F; Houghton E; Craig JV; Light K; Pizer B
Cochrane Database Syst Rev; 2010 Sep; (9):CD007786. PubMed ID: 20824866
[TBL] [Abstract][Full Text] [Related]
36. Comparative Cost-utility Analysis Between Aprepitant- and Fosaprepitant-containing Regimens To Prevent Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan.
Kashiwa M; Matsushita R
Clin Ther; 2019 May; 41(5):929-942. PubMed ID: 31036286
[TBL] [Abstract][Full Text] [Related]
37. Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients.
Shankar A; Roy S; Malik A; Julka PK; Rath GK
Asian Pac J Cancer Prev; 2015; 16(15):6207-13. PubMed ID: 26434818
[TBL] [Abstract][Full Text] [Related]
38. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy.
Ito Y; Karayama M; Inui N; Kuroishi S; Nakano H; Nakamura Y; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Hayakawa H; Suda T; Chida K
Lung Cancer; 2014 Jun; 84(3):259-64. PubMed ID: 24746177
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
De Tursi M; Carella C; Tomao S; Cinieri S; Lorusso V; Marchetti P; Vecchio S; Sansoni E; Contu A; Adamo V; Silvestris N; Nuzzo A; Rosti G; Ravaioli A; Danova M; Tonini G; Passalacqua R; Cruciani G; Faedi M; Spada M; De Laurentiis M; Amoroso D; Tomao F; Sperduti I; Grassadonia A; Tinari N; Natoli C; Iacobelli S;
Tumori; 2014; 100(6):e309-13. PubMed ID: 25688518
[TBL] [Abstract][Full Text] [Related]
40. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
